arrow

From NeuroLex

Jump to: navigation, search



Abciximab

Name: Abciximab
Description: Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Pharmacology: Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. Mechanism of action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. Drug type: Approved. Biotech. Investigational. Drug category: Anticoagulants. Antiplatelet Agents
Synonym(s): 7E3 antibody, ReoPro, abciximab, antiGPIIBIIIa, c7E3, ReoPro, ReoPro (Centocor)
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB00054
*Id: DB00054
Related to: High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor III-B, Integrin beta-3, Complement C1s subcomponent, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Ccdbuser, Nifbot2



bookmark

*Neurolex imports many terms from existing community ontologies, e.g., the Gene Ontology. We try to re-use the original identifier when possible and often import content from the original ontology. However, Neurolex is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.

Facts about AbciximabRDF feed
Commenttaken from DrugBank
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB00054  +
DefinitionFab fragment of the chimeric human-murine Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Pharmacology: Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. Mechanism of action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. Drug type: Approved. Biotech. Investigational. Drug category: Anticoagulants. Antiplatelet Agents egory: Anticoagulants. Antiplatelet Agents
Has roleDrug  +
IdDB00054  +
LabelAbciximab  +
ModifiedDate14 April 2014  +
RelatedToHigh affinity immunoglobulin gamma Fc receptor I  +, Low affinity immunoglobulin gamma Fc region receptor III-B  +, Integrin beta-3  +, Complement C1s subcomponent  +, Complement C1r subcomponent  +, Complement C1q subcomponent subunit A  +, Complement C1q subcomponent subunit B  +, Complement C1q subcomponent subunit C  +, Low affinity immunoglobulin gamma Fc region receptor III-A  +, Low affinity immunoglobulin gamma Fc region receptor II-a  +, Low affinity immunoglobulin gamma Fc region receptor II-b  +, and Low affinity immunoglobulin gamma Fc region receptor II-c  +
SuperCategoryMolecular entity  +
Synonym7E3 antibody  +, ReoPro  +, abciximab  +, antiGPIIBIIIa  +, c7E3  +, and ReoPro (Centocor)  +